More than a decade ago, apolipoprotein L1 (APOL1) risk alleles designated G1 and G2, were discovered to be causally associated with markedly increased risk for progressive kidney disease in individuals of recent African ancestry. Gratifying progress has been made during the intervening years, extending to the development and clinical testing of genomically precise small molecule therapy accompanied by emergence of RNA medicine platforms and clinical testing within just over a decade.

中文翻译：

---

APOL1 肾病 - 群体遗传学的成功故事。

十多年前，人们发现载脂蛋白 L1 (APOL1) 风险等位基因 G1 和 G2 与近代非洲血统的个体患进展性肾病的风险显着增加存在因果关系。近几年来，我们取得了可喜的进展，在短短十多年的时间里，基因组精确小分子疗法的开发和临床测试，伴随着RNA医学平台和临床测试的出现。